Switch theme
Sign up to access all valuation multiples
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
1997
7.6K+
LTM Revenue $9.5B
LTM EBITDA $3.3B
$21.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biogen has a last 12-month revenue of $9.5B and a last 12-month EBITDA of $3.3B.
In the most recent fiscal year, Biogen achieved revenue of $9.7B and an EBITDA of $2.8B.
Biogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biogen valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $9.8B | $9.7B | XXX | XXX | XXX |
| Gross Profit | $7.9B | $7.3B | XXX | XXX | XXX |
| Gross Margin | 80% | 75% | XXX | XXX | XXX |
| EBITDA | $2.0B | $2.8B | XXX | XXX | XXX |
| EBITDA Margin | 21% | 29% | XXX | XXX | XXX |
| Net Profit | $3.0B | $1.2B | XXX | XXX | XXX |
| Net Margin | 31% | 12% | XXX | XXX | XXX |
| Net Debt | $2.9B | $5.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Biogen's stock price is $119.
Biogen has current market cap of $17.5B, and EV of $21.7B.
See Biogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21.7B | $17.5B | XXX | XXX | XXX | XXX | $16.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Biogen has market cap of $17.5B and EV of $21.7B.
Biogen's trades at 2.3x LTM EV/Revenue multiple, and 6.5x LTM EBITDA.
Analysts estimate Biogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Biogen and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $21.7B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 7.7x | XXX | XXX | XXX |
| P/E | 10.7x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 8.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBiogen's NTM/LTM revenue growth is -4%
Biogen's revenue per employee for the last fiscal year averaged $1.3M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Biogen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Biogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Biogen and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 53% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biogen acquired XXX companies to date.
Last acquisition by Biogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Biogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Biogen founded? | Biogen was founded in 1997. |
| Where is Biogen headquartered? | Biogen is headquartered in United States of America. |
| How many employees does Biogen have? | As of today, Biogen has 7.6K+ employees. |
| Who is the CEO of Biogen? | Biogen's CEO is Mr. Christopher A. Viehbacher. |
| Is Biogen publicy listed? | Yes, Biogen is a public company listed on NAS. |
| What is the stock symbol of Biogen? | Biogen trades under BIIB ticker. |
| When did Biogen go public? | Biogen went public in 1991. |
| Who are competitors of Biogen? | Similar companies to Biogen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Biogen? | Biogen's current market cap is $17.5B |
| What is the current revenue of Biogen? | Biogen's last 12-month revenue is $9.5B. |
| What is the current EBITDA of Biogen? | Biogen's last 12-month EBITDA is $3.3B. |
| What is the current EV/Revenue multiple of Biogen? | Current revenue multiple of Biogen is 2.3x. |
| What is the current EV/EBITDA multiple of Biogen? | Current EBITDA multiple of Biogen is 6.5x. |
| What is the current revenue growth of Biogen? | Biogen revenue growth between 2023 and 2024 was -2%. |
| Is Biogen profitable? | Yes, Biogen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
